FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285012725> ?p ?o ?g. }

• W4285012725 endingPage "943" @default.
• W4285012725 startingPage "939" @default.
• W4285012725 abstract "Transgender persons have an increased vulnerability to HIV infection yet have not been well-represented in past clinical trials for pre-exposure prophylaxis (PrEP). Because of this, there are few data available to understand whether gender-affirming hormone concentrations are influenced by PrEP agents in transgender men (TM) and transgender women (TW). The objective of this study was to compare gender-affirming hormone concentrations with versus without emtricitabine (F, FTC)-tenofovir disoproxil fumarate (TDF). TM and TW without HIV, aged 15-24 years, were enrolled for 1 month of directly observed daily F/TDF. Participants were required to be receiving a stable hormone dose (estradiol or testosterone) for at least 1 month or three consecutive doses, whichever was longer, before enrollment and willing to continue the same dose. Intensive pharmacokinetic (PK) sampling for gender-affirming hormones was collected before and 2-3 weeks after daily F/TDF. Serum estradiol and total testosterone were determined by liquid chromatography-tandem mass spectrometry; free testosterone by equilibrium dialysis. Maximum concentrations (Cmax) and area under the curve (AUClast) were log-transformed and compared between baseline and on F/TDF using geometric mean ratios (GMRs) with 95% confidence intervals (CIs). Twenty-five TW and 24 TM were enrolled (median age: 20 and 21 years, respectively). In TW, estradiol Cmax (GMR [95% CI]: 0.85 [0.65-1.11]) and AUClast (GMR [95% CI]: 0.87 [0.73-1.03]) were comparable on F/TDF versus baseline. In TM, similar comparability was observed for PrEP versus baseline including total testosterone Cmax (GMR [95% CI]: 0.91 [0.80-1.03]) and AUClast (GMR [95% CI]: 0.91 [0.81-1.04]) and free testosterone Cmax (GMR [95% CI]: 0.89 [0.74-1.07]) and AUClast (GMR [95% CI]: 0.88 [0.74-1.03]). Estradiol and testosterone exposures in young TW and TM did not significantly differ on F/TDF versus baseline. These findings should reassure patients and providers that F/TDF can be used as PrEP without concern for altering gender-affirming hormone PK. ClinicalTrials.gov (NCT03652623)." @default.
• W4285012725 created "2022-07-12" @default.
• W4285012725 creator A5004750769 @default.
• W4285012725 creator A5005110438 @default.
• W4285012725 creator A5025836452 @default.
• W4285012725 creator A5029372880 @default.
• W4285012725 creator A5032423155 @default.
• W4285012725 creator A5045910681 @default.
• W4285012725 creator A5054571824 @default.
• W4285012725 creator A5055653184 @default.
• W4285012725 creator A5061895818 @default.
• W4285012725 creator A5068923671 @default.
• W4285012725 creator A5077024538 @default.
• W4285012725 creator A5083657822 @default.
• W4285012725 date "2022-12-01" @default.
• W4285012725 modified "2023-09-24" @default.
• W4285012725 title "Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate" @default.
• W4285012725 cites W2103920597 @default.
• W4285012725 cites W2145754461 @default.
• W4285012725 cites W2756092087 @default.
• W4285012725 cites W2938897492 @default.
• W4285012725 cites W2958483693 @default.
• W4285012725 cites W2984468121 @default.
• W4285012725 cites W3009036865 @default.
• W4285012725 cites W3048330536 @default.
• W4285012725 doi "https://doi.org/10.1089/aid.2022.0044" @default.
• W4285012725 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35815468" @default.
• W4285012725 hasPublicationYear "2022" @default.
• W4285012725 type Work @default.
• W4285012725 citedByCount "3" @default.
• W4285012725 countsByYear W42850127252022 @default.
• W4285012725 countsByYear W42850127252023 @default.
• W4285012725 crossrefType "journal-article" @default.
• W4285012725 hasAuthorship W4285012725A5004750769 @default.
• W4285012725 hasAuthorship W4285012725A5005110438 @default.
• W4285012725 hasAuthorship W4285012725A5025836452 @default.
• W4285012725 hasAuthorship W4285012725A5029372880 @default.
• W4285012725 hasAuthorship W4285012725A5032423155 @default.
• W4285012725 hasAuthorship W4285012725A5045910681 @default.
• W4285012725 hasAuthorship W4285012725A5054571824 @default.
• W4285012725 hasAuthorship W4285012725A5055653184 @default.
• W4285012725 hasAuthorship W4285012725A5061895818 @default.
• W4285012725 hasAuthorship W4285012725A5068923671 @default.
• W4285012725 hasAuthorship W4285012725A5077024538 @default.
• W4285012725 hasAuthorship W4285012725A5083657822 @default.
• W4285012725 hasConcept C11171543 @default.
• W4285012725 hasConcept C112705442 @default.
• W4285012725 hasConcept C126322002 @default.
• W4285012725 hasConcept C142462285 @default.
• W4285012725 hasConcept C15744967 @default.
• W4285012725 hasConcept C159047783 @default.
• W4285012725 hasConcept C22979827 @default.
• W4285012725 hasConcept C2776939746 @default.
• W4285012725 hasConcept C2776983459 @default.
• W4285012725 hasConcept C2777068322 @default.
• W4285012725 hasConcept C2777911890 @default.
• W4285012725 hasConcept C2779279991 @default.
• W4285012725 hasConcept C2779496540 @default.
• W4285012725 hasConcept C2779671885 @default.
• W4285012725 hasConcept C2779778239 @default.
• W4285012725 hasConcept C2993143319 @default.
• W4285012725 hasConcept C30092816 @default.
• W4285012725 hasConcept C3013748606 @default.
• W4285012725 hasConcept C42407357 @default.
• W4285012725 hasConcept C44249647 @default.
• W4285012725 hasConcept C71315377 @default.
• W4285012725 hasConcept C71924100 @default.
• W4285012725 hasConcept C98274493 @default.
• W4285012725 hasConceptScore W4285012725C11171543 @default.
• W4285012725 hasConceptScore W4285012725C112705442 @default.
• W4285012725 hasConceptScore W4285012725C126322002 @default.
• W4285012725 hasConceptScore W4285012725C142462285 @default.
• W4285012725 hasConceptScore W4285012725C15744967 @default.
• W4285012725 hasConceptScore W4285012725C159047783 @default.
• W4285012725 hasConceptScore W4285012725C22979827 @default.
• W4285012725 hasConceptScore W4285012725C2776939746 @default.
• W4285012725 hasConceptScore W4285012725C2776983459 @default.
• W4285012725 hasConceptScore W4285012725C2777068322 @default.
• W4285012725 hasConceptScore W4285012725C2777911890 @default.
• W4285012725 hasConceptScore W4285012725C2779279991 @default.
• W4285012725 hasConceptScore W4285012725C2779496540 @default.
• W4285012725 hasConceptScore W4285012725C2779671885 @default.
• W4285012725 hasConceptScore W4285012725C2779778239 @default.
• W4285012725 hasConceptScore W4285012725C2993143319 @default.
• W4285012725 hasConceptScore W4285012725C30092816 @default.
• W4285012725 hasConceptScore W4285012725C3013748606 @default.
• W4285012725 hasConceptScore W4285012725C42407357 @default.
• W4285012725 hasConceptScore W4285012725C44249647 @default.
• W4285012725 hasConceptScore W4285012725C71315377 @default.
• W4285012725 hasConceptScore W4285012725C71924100 @default.
• W4285012725 hasConceptScore W4285012725C98274493 @default.
• W4285012725 hasIssue "12" @default.
• W4285012725 hasLocation W42850127251 @default.
• W4285012725 hasLocation W42850127252 @default.
• W4285012725 hasOpenAccess W4285012725 @default.
• W4285012725 hasPrimaryLocation W42850127251 @default.
• W4285012725 hasRelatedWork W1976801771 @default.
• W4285012725 hasRelatedWork W1992141591 @default.

• next